Your browser is no longer supported. Please, upgrade your browser.
Allogene Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.88 Insider Own18.50% Shs Outstand137.03M Perf Week-0.44%
Market Cap2.46B Forward P/E- EPS next Y-2.59 Insider Trans-0.22% Shs Float74.43M Perf Month12.80%
Income-250.70M PEG- EPS next Q-0.90 Inst Own62.90% Short Float6.37% Perf Quarter-26.31%
Sales38.40M P/S64.07 EPS this Y-13.80% Inst Trans2.81% Short Ratio2.54 Perf Half Y-30.04%
Book/sh7.08 P/B2.54 EPS next Y-32.80% ROA-21.70% Target Price35.19 Perf Year-43.48%
Cash/sh3.53 P/C5.09 EPS next 5Y1.00% ROE-24.20% 52W Range12.90 - 39.12 Perf YTD-28.76%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-54.04% Beta-
Dividend %- Quick Ratio9.40 Sales past 5Y- Gross Margin- 52W Low39.38% ATR0.94
Employees301 Current Ratio9.40 Sales Q/Q- Oper. Margin- RSI (14)44.18 Volatility5.43% 5.56%
OptionableYes Debt/Eq0.00 EPS Q/Q-9.60% Profit Margin- Rel Volume0.40 Prev Close18.67
ShortableYes LT Debt/Eq0.00 EarningsNov 04 AMC Payout- Avg Volume1.87M Price17.98
Recom1.70 SMA20-4.93% SMA50-9.87% SMA200-31.27% Volume741,288 Change-3.70%
Oct-20-21Initiated Cowen Outperform
Oct-08-21Downgrade Stifel Buy → Hold $44 → $18
Oct-08-21Downgrade Goldman Buy → Neutral $71 → $20
Sep-23-21Upgrade Raymond James Mkt Perform → Outperform
Jun-21-21Resumed Jefferies Buy $53
May-20-21Upgrade Truist Hold → Buy $34 → $41
May-14-21Initiated B. Riley Securities Buy $52
Jan-26-21Upgrade Stifel Hold → Buy $33 → $43
Dec-10-20Resumed H.C. Wainwright Buy $40
Nov-24-20Initiated BofA Securities Buy $41
Oct-23-20Initiated RBC Capital Mkts Outperform $55
Jun-01-20Downgrade Raymond James Outperform → Mkt Perform
May-29-20Reiterated H.C. Wainwright Buy $42 → $55
May-19-20Upgrade ROTH Capital Neutral → Buy $26 → $60
May-15-20Upgrade Guggenheim Neutral → Buy
May-14-20Reiterated H.C. Wainwright Buy $35 → $42
May-14-20Downgrade SunTrust Buy → Hold $29 → $32
Apr-13-20Initiated SunTrust Buy $29
Mar-13-20Initiated H.C. Wainwright Buy $35
Mar-05-20Initiated Stifel Hold $27
Nov-12-21 08:30AM  
Nov-09-21 09:15AM  
Nov-05-21 11:19AM  
Nov-04-21 04:02PM  
Nov-01-21 04:57PM  
Oct-28-21 08:30AM  
Oct-15-21 09:00PM  
Oct-14-21 06:52AM  
Oct-13-21 05:15PM  
Oct-12-21 06:07AM  
Oct-11-21 07:52PM  
Oct-08-21 10:08PM  
Oct-07-21 06:11PM  
Sep-20-21 08:30AM  
Sep-03-21 11:31AM  
Sep-01-21 08:30AM  
Aug-13-21 11:38AM  
Aug-12-21 08:30AM  
Aug-07-21 03:03AM  
Aug-05-21 09:57AM  
Aug-04-21 04:02PM  
Aug-03-21 01:25AM  
Aug-02-21 08:30AM  
Jul-27-21 08:30AM  
Jul-21-21 04:32AM  
Jul-12-21 08:30AM  
Jul-01-21 11:25AM  
Jun-30-21 08:30AM  
Jun-21-21 07:00AM  
Jun-07-21 11:11AM  
Jun-04-21 11:31AM  
May-20-21 04:18PM  
May-19-21 04:51PM  
May-12-21 08:30AM  
May-06-21 10:24AM  
May-05-21 06:05PM  
Apr-28-21 09:24AM  
Apr-27-21 08:30AM  
Apr-22-21 10:25AM  
Apr-21-21 08:30AM  
Apr-19-21 08:30AM  
Apr-12-21 08:30AM  
Apr-10-21 08:30AM  
Mar-27-21 11:31AM  
Feb-26-21 08:57AM  
Feb-25-21 04:02PM  
Feb-18-21 08:30AM  
Feb-09-21 08:30AM  
Jan-26-21 08:30AM  
Jan-10-21 11:35PM  
Jan-05-21 08:30AM  
Dec-24-20 10:47AM  
Dec-23-20 11:30AM  
Dec-18-20 09:30PM  
Dec-15-20 06:00AM  
Dec-07-20 12:40PM  
Dec-06-20 10:00AM  
Dec-05-20 12:30PM  
Dec-04-20 11:31AM  
Dec-02-20 08:30AM  
Nov-12-20 08:30AM  
Nov-08-20 11:04AM  
Nov-04-20 12:44PM  
Oct-27-20 08:30AM  
Oct-24-20 08:55AM  
Oct-21-20 10:02AM  
Oct-15-20 08:00AM  
Sep-29-20 06:48PM  
Sep-04-20 11:31AM  
Sep-02-20 08:30AM  
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for treating R/R multiple myeloma; ALLO-819, an allogeneic CAR T cell product candidates for the treatment of acute myeloid leukemia; ALLO-605, an allogeneic CAR T cell product candidate for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; and DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc., as well as clinical trial collaboration agreement with SpringWorks Therapeutics, Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. The company was founded in 2017 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Amado RafaelEVP of R&D and CMOOct 01Sale24.3511,507280,185323,928Oct 04 05:55 PM
Bhavnagri VeerGeneral CounselSep 15Option Exercise2.275,00011,350426,669Sep 17 04:44 PM
Bhavnagri VeerGeneral CounselSep 15Sale24.775,000123,844421,669Sep 17 04:44 PM
WITTE OWEN N.DirectorSep 09Sale25.545,000127,700221,182Sep 09 05:32 PM
WITTE OWEN N.DirectorAug 20Sale23.4710,000234,700226,182Aug 23 04:22 PM
Bhavnagri VeerGeneral CounselAug 16Option Exercise2.275,00011,350426,353Aug 17 04:05 PM
Bhavnagri VeerGeneral CounselAug 16Sale21.005,000104,994421,353Aug 17 04:05 PM
Bhavnagri VeerGeneral CounselJul 15Option Exercise2.275,00011,350426,353Jul 16 04:14 PM
Bhavnagri VeerGeneral CounselJul 15Sale21.555,000107,753421,353Jul 16 04:14 PM
Bhavnagri VeerGeneral CounselJun 15Option Exercise2.275,00011,350426,353Jun 16 05:00 PM
Bhavnagri VeerGeneral CounselJun 15Sale25.325,000126,600421,353Jun 16 05:00 PM
WITTE OWEN N.DirectorJun 09Sale25.059,969249,723236,182Jun 11 05:48 PM
Belldegrun ArieDirectorMay 24Option Exercise18.22379,0666,906,583583,034May 25 08:00 AM
SCHMIDT ERIC THOMASChief Financial OfficerMay 24Option Exercise18.2214,897271,423110,994May 26 08:00 AM
Chang David DPresident and CEOMay 24Option Exercise18.2227,410499,4102,312,279May 26 08:00 AM
Bhavnagri VeerGeneral CounselMay 18Option Exercise2.275,00011,350426,353May 20 05:19 PM
Bhavnagri VeerGeneral CounselMay 18Sale30.005,000150,000421,353May 20 05:19 PM
Bhavnagri VeerGeneral CounselApr 15Option Exercise2.2710,00022,700431,353Apr 16 04:07 PM
Bhavnagri VeerGeneral CounselApr 15Sale32.0510,000320,517421,353Apr 16 04:07 PM
Bhavnagri VeerGeneral CounselMar 15Option Exercise2.2710,00022,700415,774Mar 17 05:00 PM
Bhavnagri VeerGeneral CounselMar 15Sale37.9516,623630,798399,151Mar 17 05:00 PM
Chang David DPresident and CEOMar 15Sale38.5720,513791,2712,204,417Mar 17 05:00 PM
Amado RafaelEVP of R&D and CMOMar 15Sale38.052,798106,471110,035Mar 17 05:01 PM
SCHMIDT ERIC THOMASChief Financial OfficerMar 15Sale38.238,053307,88971,231Mar 17 05:00 PM
MOORE ALISONChief Technical OfficerMar 15Sale38.146,164235,089102,574Mar 17 05:00 PM
SCHMIDT ERIC THOMASChief Financial OfficerJan 15Sale32.2615,000483,8591,152,595Jan 19 04:31 PM
SCHMIDT ERIC THOMASChief Financial OfficerJan 14Sale30.7715,000461,6101,167,595Jan 19 04:31 PM
Bhavnagri VeerGeneral CounselDec 17Option Exercise2.2751,500116,905405,402Dec 18 04:34 PM